Vaniprevir

Vaniprevir
Names
IUPAC name
(1R,21S,24S)-21-tert-Butyl-N-((1R,2R)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-ethylcyclopropyl)-16,16-dimethyl-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,7.06,11]-heptacosa-6,8,10-triene-24-carboxamide
Identifiers
CAS Number
  • 923590-37-8
3D model (JSmol)
  • Interactive image
ChEBI
  • CHEBI:136047
ChEMBL
  • ChEMBL599872
ChemSpider
  • 24651717
DrugBank
  • DB11929
ECHA InfoCard 100.207.830 Edit this at Wikidata
EC Number
  • 682-506-7
KEGG
  • D09987
PubChem CID
  • 24765256
UNII
  • CV3X74AO1H checkY
InChI
  • InChI=1S/C38H55N5O9S/c1-7-25-18-38(25,33(46)41-53(49,50)27-14-15-27)40-31(44)29-17-26-20-43(29)32(45)30(36(2,3)4)39-34(47)51-22-37(5,6)16-9-8-11-23-12-10-13-24-19-42(21-28(23)24)35(48)52-26/h10,12-13,25-27,29-30H,7-9,11,14-22H2,1-6H3,(H,39,47)(H,40,44)(H,41,46)/t25-,26-,29+,30-,38-/m1/s1
    Key: KUQWGLQLLVFLSM-ONAXAZCASA-N
  • CC(C)(C)[C@H]1NC(=O)OCC(C)(C)CCCCc2cccc3CN(Cc23)C(=O)O[C@H]4C[C@@H](N(C4)C1=O)C(=O)N[C@@]5(C[C@H]5C=C)C(=O)NS(=O)(=O)C6CC6
Properties
Chemical formula
 C38H55N5O9S
Molar mass 757.94 g·mol−1
Appearance White powder
Hazards
GHS labelling:
Pictograms
 GHS08: Health hazard
Warning
Hazard statements
 H373
Precautionary statements
 P260, P314, P501
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
Chemical compound

Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) NS3/4A protease inhibitor, developed by Merck & Co., which is currently in clinical testing.[1] In Japan, it was approved for treating hepatitis C in 2014 under the brand name Vanihep.[2][3]

References

  1. ^ McCauley JA, McIntyre CJ, Rudd MT, Nguyen KT, Romano JJ, Butcher JW, Gilbert KF, Bush KJ, Holloway MK, Swestock J, Wan BL, Carroll SS, DiMuzio JM, Graham DJ, Ludmerer SW, Mao SS, Stahlhut MW, Fandozzi CM, Trainor N, Olsen DB, Vacca JP, Liverton NJ (March 2010). "Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor". J. Med. Chem. 53 (6): 2443–63. doi:10.1021/jm9015526. PMID 20163176.
  2. ^ "First recommendation for HCV drug vaniprevir, in Japan". datamonitorhealthcare.com. September 25, 2014.
  3. ^ "New Drugs Approved" (PDF). Pharmaceuticals and Medical Devices Agency. {{cite journal}}: Cite journal requires |journal= (help)
  • v
  • t
  • e
RNA virus antivirals (primarily J05, also S01AD and D06BB)
Hepatitis C
NS3/4A protease inhibitors (–previr)
NS5A inhibitors (–asvir)
NS5B RNA polymerase inhibitors (–buvir)
Combination drugs
Hepatitis DPicornavirusAnti-influenza agentsMultiple/general
Interferon
3CL protease inhibitors (–trelvir)
RNA pol inhibitors
Multiple/Unknown/Other
Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e